<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cilostazol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cilostazol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cilostazol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12158" href="/d/html/12158.html" rel="external">see "Cilostazol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F7885909"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Contraindicated in heart failure patients:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cilostazol is contraindicated with patients with heart failure of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared with placebo in patients with class III to IV heart failure.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F151461"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiplatelet Agent;</li>
<li>
                        Phosphodiesterase-3 Enzyme Inhibitor;</li>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F151445"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e850078-b62e-4303-98c0-fc362652a111">Intermittent claudication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intermittent claudication:</b>
<b>Oral:</b> 100 mg twice daily. <b>Note:</b> The American College of Chest Physicians recommends use when refractory to exercise therapy and smoking cessation; use in combination with either aspirin or clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Discontinue treatment if symptoms are not improved after 3 months of therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ba0ef745-05ee-43a3-8e63-f95b2f0ae155">PCI</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>PCI (following elective stent placement) (off-label use):</b>
<b>Oral:</b> 100 mg twice daily in combination with aspirin or clopidogrel. <b>Note:</b> Only recommended in patients with an allergy or intolerance to either aspirin or clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315257'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="500509fd-e23d-40ef-8519-2601053ed343">Secondary prevention of noncardioembolic stroke or TIA</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary prevention of noncardioembolic stroke or TIA (off-label use):</b>
<b>Oral:</b> 100 mg twice daily. <b>Note:</b> Clopidogrel or aspirin/extended release dipyridamole recommended over the use of cilostazol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315257'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991729"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary. Severe renal impairment increases metabolite concentrations; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease (ESRD) on dialysis: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989057"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution.</p></div>
<div class="block doe drugH1Div" id="F151446"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F151417"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (27% to 34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (12% to 19%), abnormal stools (12% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (10% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (7% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations (5% to 10%), peripheral edema (7% to 9%), tachycardia (4%), atrial fibrillation (&lt;2%), atrial flutter (&lt;2%), cardiac arrest (&lt;2%), cardiac failure (&lt;2%), cerebral infarction (&lt;2%), edema (&lt;2%), facial edema (&lt;2%), hypotension (&lt;2%), myocardial infarction (&lt;2%), nodal arrhythmia (&lt;2%), orthostatic hypotension (&lt;2%), supraventricular tachycardia (&lt;2%), syncope (&lt;2%), varicose veins (&lt;2%), ventricular premature contractions (&lt;2%), ventricular tachycardia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (9% to 10%), vertigo (3%) , anxiety (&lt;2%), chills (&lt;2%), insomnia (&lt;2%), malaise (&lt;2%), neuralgia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymoses (&lt;2%), furunculosis (eye: &lt;2%), skin hypertrophy (&lt;2%), urticaria (&lt;2%), xeroderma (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria (&lt;2%), diabetes mellitus (&lt;2%), gout (&lt;2%), hyperlipidemia (&lt;2%), hyperuricemia (&lt;2%), increased gamma-glutamyl transferase (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (7%), dyspepsia (6%), abdominal pain (4% to 5%), flatulence (3%), anorexia (&lt;2%), cholelithiasis (&lt;2%), colitis (&lt;2%), duodenal ulcer (&lt;2%), duodenitis (&lt;2%), esophageal hemorrhage (&lt;2%), esophagitis (&lt;2%), gastric ulcer (&lt;2%), gastritis (&lt;2%), gastroenteritis (&lt;2%), gingival hemorrhage (&lt;2%), hematemesis (&lt;2%), melena (&lt;2%), peptic ulcer (&lt;2%), periodontal abscess (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (&lt;2%), pelvic pain (&lt;2%), urinary frequency (&lt;2%), vaginal hemorrhage (&lt;2%), vaginitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;2%), hemorrhage (&lt;2%), hemorrhage (eye, &lt;2%), iron deficiency anemia (&lt;2%), polycythemia (&lt;2%), purpura (&lt;2%), rectal hemorrhage (&lt;2%), retroperitoneal hemorrhage (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Tongue edema (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (7%), myalgia (3%), arthralgia (&lt;2%), bursitis (&lt;2%), neck stiffness (&lt;2%), ostealgia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (&lt;2%), blindness (&lt;2%), conjunctivitis (&lt;2%), diplopia (&lt;2%), retinal hemorrhage (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (&lt;2%), tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (10%), cough (3% to 4%), asthma (&lt;2%), epistaxis (&lt;2%), hemoptysis (&lt;2%), pneumonia (&lt;2%), sinusitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Abnormal hepatic function tests, agranulocytosis, anaphylaxis, angina pectoris, angioedema, aplastic anemia, cerebrovascular accident, cerebral hemorrhage, chest pain, coronary thrombosis (stent), fixed drug eruption, gastrointestinal hemorrhage, granulocytopenia, hematoma (extradural), hematuria, hemorrhagic diathesis, hepatic insufficiency, hot flash, hyperglycemia, hypersensitivity, hypertension, increased blood pressure, increased blood urea nitrogen, interstitial pneumonitis, intracranial hemorrhage, jaundice, left ventricular dysfunction (outflow tract obstruction; in patients with sigmoid-shaped interventricular septum), leukopenia, pain, pancytopenia, pulmonary hemorrhage, pruritus, prolonged QT interval on ECG, skin rash, Stevens-Johnson syndrome, subcutaneous hemorrhage, subdural hematoma, thrombocytopenia, thrombosis, torsades de pointes, vasodilation, vomiting</p></div>
<div class="block coi drugH1Div" id="F151427"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cilostazol or any component of the formulation; heart failure of any severity.</p></div>
<div class="block war drugH1Div" id="F151414"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: May induce tachycardia, palpitation, tachyarrhythmia, and/or hypotension. Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum; monitor for the development of a new systolic murmur or cardiac symptoms after initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Cases of thrombocytopenia or leukopenia progressing to agranulocytosis, reversible upon discontinuation, have been reported when not immediately discontinued; monitor platelets and white blood cell counts periodically.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hemostatic disorders: Avoid use in patients with active pathological bleeding or hemostatic disorders (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: <b>[US Boxed Warning]: Cilostazol is contraindicated in patients with heart failure of any severity. Phosphodiesterase inhibitors have caused decreased survival compared with placebo in patients with class III to IV heart failure.</b> Patients with history of ischemic heart disease may be at increased risk for exacerbation of angina pectoris or myocardial infarction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elective surgery: Time required to recover adequate platelet function is ~2 days (Hill 2011). Of note, bleeding times were not significantly altered by cilostazol after 3 to 14 days of treatment (Kim 2004; Wilhite 2003).</p></div>
<div class="block foc drugH1Div" id="F151423"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F151410"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F151428"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cilostazol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.82 - $1.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.82</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F5582346"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer 30 minutes before or 2 hours after meals (breakfast and dinner). </p></div>
<div class="block use drugH1Div" id="F151424"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Intermittent claudication: </b>Reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. </p></div>
<div class="block off-label drugH1Div" id="F25475326"><span class="drugH1">Use: Off-Label: Adult</span><p>Elective PCI with bare metal or drug eluting stent placement (alternative agent); Secondary prevention of noncardioembolic ischemic stroke or transient ischemic attack (TIA)</p></div>
<div class="block mst drugH1Div" id="F151468"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pletal may be confused with Plendil</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F151454"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (major), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F151419"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the adverse/toxic effect of Cilostazol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Inhibitors of Equilibrative Nucleoside (ENT1) and Concentrative Nucleoside (CNT3) Transport Proteins may increase the serum concentration of Cladribine.  Management: Avoid concomitant use of ENT1 or CNT3 inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider an ENT1 or CNT3 inhibitor dose reduction and separation in the timing of administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Cilostazol. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Cilostazol. Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving moderate inhibitors of CYP2C19. Monitor clinical response to cilostazol closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Cilostazol. Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cilostazol. Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esomeprazole: May increase serum concentrations of the active metabolite(s) of Cilostazol. Esomeprazole may increase the serum concentration of Cilostazol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: May increase serum concentrations of the active metabolite(s) of Cilostazol. Omeprazole may increase the serum concentration of Cilostazol. Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving omeprazole. Monitor clinical response to cilostazol closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Cilostazol may enhance the hypotensive effect of Riociguat.  Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticlopidine: May increase serum concentrations of the active metabolite(s) of Cilostazol. Ticlopidine may increase the serum concentration of Cilostazol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: May increase the serum concentration of Cilostazol.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F151438"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Taking cilostazol with a high-fat meal may increase peak concentration by 90% and increase AUC by 25%. Grapefruit juice may increase serum levels of cilostazol and enhance toxic effects. Management: Administer cilostazol on an empty stomach 30 minutes before or 2 hours after meals. Concurrent ingestion of grapefruit juice may require therapy modification; consult drug interactions database for more detailed information.</p></div>
<div class="block pri drugH1Div" id="F151429"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F151430"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if cilostazol is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F27978540"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Platelets and WBC counts periodically; monitor for the development of a new systolic murmur or cardiac symptoms.</p></div>
<div class="block pha drugH1Div" id="F151413"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cilostazol and its metabolites are inhibitors of phosphodiesterase III. As a result, cyclic AMP is increased leading to reversible inhibition of platelet aggregation, vasodilation, and inhibition of vascular smooth muscle cell proliferation. </p></div>
<div class="block phk drugH1Div" id="F151426"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Effect on walking distance: 2 to 4 weeks; may require up to 12 weeks </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Cilostazol 95% to 98%; active metabolites: 66% to 97%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; CYP1A2 (minor), CYP2C19 (major), CYP2D6 (minor), CYP3A4 (major).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~11 to 13 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (74%) and feces (20%) as metabolites</p></div>
<div class="block phksp drugH1Div" id="F51220836"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Severe renal impairment increases metabolite concentrations and alters protein binding of the parent drug.</p>
<p style="text-indent:-2em;margin-left:2em;">Cigarette smoking: Exposure is decreased by ~20% in smokers.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F151432"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Pletal</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aclusin | Cibrogan | Cilaal | Cilospaw | Cilostal | Cilostane | Cilostazol richet | Cilovas | Citalexon | Corionil | Dencilox | Licuagen | Novamas | Pletaal | Policor | Trastocir | Trombonot | Vasativ xr | Zolplat</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Pletal</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cilosta | Claudinil | Inclaud | Vasocil | Zocil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol sandoz | Cilostazol stada | Lostrazin | Trombye</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cebralat | Claudic | Vasativ | Vasogard</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Artesol | Cilosvitae | Clauter | Ilostal | Kostal</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">BANG PING | Pletaal | Si te li pu | Xi luo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Angiovan | Aritan | Cilostal | Cilosvitae | Cirvenzol | Licuagen | Ligamax | Praxocol | Sadoxol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol apotex | Cilostazol stada | Cilozek | Claudienne | Claudine | Noclaud | Pladizol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol al | Cilostazol hexal | Cilostazol stada | Pladizol | Pletal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ceudal | Cilostal | Cilostal xr | Cilosvitae | Citazol | Licuagen | Pletazol | Policor | Sadoxol | Xiltos 100</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aclusin | Artesol | Cilostal | Cilosvitae | Clauter</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cilozek</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cilobiogen | Cilomepatal | Cilostalon | Claudicat | Claudol | Cludalost | Coaguless | Infarca | Movigretal | Pletaal | Sedotazole | Sercprove | Stazola | Stazotrend</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol cinfa | Cilostazol kern pharma | Cilostazol midas | Cilostazol mylan | Cilostazol normon | Cilostazol pensa | Cilostazol ratiopharm | Cilostazol sandoz | Cilostazol stada genericos | Cilostazol tarbis | Cilostazol teva | Cilostazol vir | Cilostazol zentiva | Ekistol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Pletal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cilos | Cilostazol/adamed | Cilostazol/galenica | Claudiasil | Inclaud</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Pletaal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Antaclast | Cilopeda | Cilostazol hspt | Cilozek | Noclaud</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aggravan | Agrezol | Alista | Antiplat | Citaz | Fibrozol | Ilos | Naletal | Pletaal | Qital | Stazol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pletal</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cilesta | Cilodoc | Cilokem | Cilotab | Cletus | Clotazole | Pencil | Pletoz | Preclaud | Silosta | Stiloz | Vascilol | Zilast</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Albaten | Boiser | Cilostazolo Mylan | Cilostazolo sandoz | Fripass | Pletal</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aitant | Cilosinamin | Cilosmerck | Cilostate | Cilostazol jg | Ecbarl | Ejennu | Fantezole | Fantezole alfresa | Flenied | Gront | Hordazol sanken | Hordazol y.taisho | Kortrythm | Opetarl | Platemeel | Plestazol | Plestazol chemipha | Pletaal | Pletmol | Prelazine | Ranomin | Rotazona | Rotazona choseido</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Stiloz</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ahngook cilostazol | Alvogen cilostazol | Celetal | Celetal sr | Cilazol | Cilbesta | Cilbesta SR | Cilenta sr | Cilental | Cilental cr | Ciletal | Ciletal sr | Cilo k sr | Cilo m | Cilo v | Cilobell | Cilodil sr | Ciloen | Cilof | Cilogen | Cilontas | Ciloretal sr | Cilos | Cilos xr | Cilosta m | Cilosta m sr | Cilosta sr | Cilostal | Cilostan | Cilostin | Cilosto | Cilosto sr | Cilota | Cilotal | Cilotan | Cilotan sr | Cilotazole | Cilotec sr | Cilotel | Cilotel sr | Cilothera | Cilotin sr | Ciloto | Cilover sr | Cilozen | Cilsta | Ciltazol | Cilvesta sr | Citazol | Citazol sr | Daewoong cilostazol | Daewoong cilostazol sr | Hanlim cilostazol | Hucilo | Husilo sr | J letal cr | Jcilo cr | Kb stazol | Kbstazol | Kbstazol sr | Losazol | Losazol cr | Lostal | Lotasil | Lotazol | Lozence | Newta | Nocles | Plecilo sr | Pletaal | Plezol sr | Precilo sr | Prestazol | Preta | Preta sr | Pretol | Prostal | Prostal sr | Rostal | S cilo | S cilo SR | Samsung cilostazol | Samsung cilostazol SR | Smizol | Stazol | Tarocil | Unistal | Unistal sr | Unitazol | Uretazol sr</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Pletoz</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dilsatan | Pletal | Sollazon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dilsatan | Sollazon</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Caudaline | Clauter | Joustox | Raamtol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cilosol | Pletaal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Pletal</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cilostal | Cilosvitae | Clauter | Pletaal</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ciletin | Cilostan cr | Clazol | Closcizol | Clostelo | Pencil | Platecil | Pletaal | Pletaxol | Stiloz | Thromzol | Trombocil | Vaxol | Zatsol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cilosta | Cilovas | Kladica | Labista | Lostaz | Pletaal | Walk Aid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol LEK AM | Cilostop | Cilozek | Decilosal | Noclaud | Pletal | Stepcil</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pletal</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol ferrer</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol quimfa | Ciltaz | Seclodin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol galenica | Dilvas | Noclaud | Pladizol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aducil | Pletax | Pletazol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol 2care4 | Cilostazol ebb | Cilostazol eql pharma | Pletal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cilostazol stada | Cilozek | Claudine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cilosol | Citazol | Cylozza | Pletaal</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Silnorm</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cistazol | Loata | Pletaal | Pleya | Tilor</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Claudiex | Plestazol | Pletol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cilozol | Policor | Sadoxol | Vasogard</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cilostal | Hatial</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10702884">
<a name="10702884"></a>Bramer SL, Forbes WP. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol. <i>Clin Pharmacokinet</i>. 1999;37(suppl 2):25-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cilostazol-drug-information/abstract-text/10702884/pubmed" id="10702884" target="_blank">10702884</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cilostazol [prescribing information]. Columbus, OH: Slate Run Pharmaceuticals LLC; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23098967">
<a name="23098967"></a>Ferraris VA, Saha SP, Oestreich JH, et al, “2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,” <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cilostazol-drug-information/abstract-text/23098967/pubmed" id="23098967" target="_blank">23098967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cilostazol-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cilostazol-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549646">
<a name="16549646"></a>Hirsch AT, Haskal ZJ, Hertzer NR, et al, “ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary. A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),” <i>Circulation </i>, 2006, 113(11):e463-654. Available at http://www.acc.org/clinical/guidelines/pad/index.pdf
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cilostazol-drug-information/abstract-text/16549646/pubmed" id="16549646" target="_blank">16549646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15261228">
<a name="15261228"></a>Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. <i>J Clin Neurosci</i>. 2004;11(6):600-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cilostazol-drug-information/abstract-text/15261228/pubmed" id="15261228" target="_blank">15261228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10702885">
<a name="10702885"></a>Mallikaarjun S, Forbes WP, Bramer SL. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites. <i>Clin Pharmacokinet</i>. 1999;37(Suppl 2):33-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cilostazol-drug-information/abstract-text/10702885/pubmed" id="10702885" target="_blank">10702885</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pletal (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14560218">
<a name="14560218"></a>Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. <i>J Vasc Surg</i>. 2003;38(4):710-713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cilostazol-drug-information/abstract-text/14560218/pubmed" id="14560218" target="_blank">14560218</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8872 Version 341.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
